A
Aligos Therapeutics, Inc. (ALGS)
NCM – Real Time Price. Currency in USD
6.47
+0.26 (4.19%)
At close: May 12, 2026, 4:00 PM EDT
6.41
-0.06 (-0.93%)
Pre-market: May 13, 2026, 7:10 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
6.47
+0.26 (4.19%)
At close: May 12, 2026, 4:00 PM EDT
6.41
-0.06 (-0.93%)
Pre-market: May 13, 2026, 7:10 AM EDT
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Name | Position |
|---|---|
| Dr. David B. Smith Ph.D. | Executive VP & Head of Chemical Operations |
| Dr. Julian A. Symons DPHIL | Executive VP & Chief Scientific Officer |
| Dr. Kieron Wesson Ph.D. | Vice President & Head of Chemistry Manufacturing Controls |
| Dr. Lawrence M. Blatt MBA, Ph.D. | CEO, President & Chairman of the Board |
| Dr. Ramon Polo M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Global Regulatory Affairs |
| Dr. Sushmita M. Chanda DABT, Ph.D. | Executive Vice President & Chief Development Officer |
| Dr. Tse-I Lin Ph.D. | Senior VP of Early Compound Development & Belgian Site Head |
| Mr. Nikhil Aneja | Principal Accounting Officer |
| Ms. Kristina Engeseth M.B.A. | Senior VP and Head of People & Culture |
| Ms. Laura Kavanaugh | VP & Head of Legal |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 10-Q | algs-20260331.htm |
| 2026-04-29 | DEFA14A | d122092ddefa14a.htm |
| 2026-04-29 | ARS | d26899dars.pdf |
| 2026-04-21 | 8-K | d50981d8k.htm |
| 2026-04-14 | 8-K | d107028d8k.htm |
| 2026-03-05 | S-8 | d111225ds8.htm |
| 2026-02-04 | 8-K | d12642d8k.htm |
| 2025-11-06 | 10-Q | algs-20250930.htm |
| 2025-08-06 | S-8 | d25818ds8.htm |
| 2025-08-06 | 8-K | f8k_080625.htm |